Recurrent Childhood Acute Lymphoblastic Leukemia Recruiting Phase 1 Trials for Dasatinib (DB01254)

IndicationStatusPhase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs